{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:58:52Z","timestamp":1791305932941,"version":"4.3.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current guidelines discourage combined oral contraceptive (COC) use in women with hereditary thrombophilic defects. However, qualifying all hereditary thrombophilic defects as similarly strong risk factors might be questioned. Recent studies indicate the risk of venous thromboembolism (VTE) of a factor V Leiden mutation as considerably lower than a deficiency of protein C, protein S, or antithrombin. In a retrospective family cohort, the VTE risk during COC use and pregnancy (including postpartum) was assessed in 798 female relatives with or without a heterozygous, double heterozygous, or homozygous factor V Leiden or prothrombin G20210A mutation. Overall, absolute VTE risk in women with no, single, or combined defects was 0.13 (95% confidence interval 0.08-0.21), 0.35 (0.22-0.53), and 0.94 (0.47-1.67) per 100 person-years, while these were 0.19 (0.07-0.41), 0.49 (0.18-1.07), and 0.86 (0.10-3.11) during COC use, and 0.73 (0.30-1.51), 1.97 (0.94-3.63), and 7.65 (3.08-15.76) during pregnancy. COC use and pregnancy were independent risk factors for VTE, with highest risk during pregnancy postpartum, as demonstrated by adjusted hazard ratios of 16.0 (8.0-32.2) versus 2.2 (1.1-4.0) during COC use. Rather than strictly contraindicating COC use, we advocate that detailed counseling on all contraceptive options, including COCs, addressing the associated risks of both VTE and unintended pregnancy, enabling these women to make an informed choice.<\/jats:p>","DOI":"10.1182\/blood-2011-03-345678","type":"journal-article","created":{"date-parts":[[2011,6,10]],"date-time":"2011-06-10T09:11:58Z","timestamp":1307697118000},"page":"2055-2061","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":70,"title":["Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception"],"prefix":"10.1182","volume":"118","author":[{"given":"Elizabeth F. W.","family":"van Vlijmen","sequence":"first","affiliation":[{"name":"Division of Hemostasis and Thrombosis, Department of Hematology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nic J. G. M.","family":"Veeger","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, University Medical Center Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Middeldorp","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karly","family":"Hamuly\u00e1k","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Clinical Epidemiology, University Hospital Maastricht, Maastricht, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Prins","sequence":"additional","affiliation":[{"name":"Medical Technology Assessment, University Hospital Maastricht, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry R.","family":"B\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[{"name":"Division of Hemostasis and Thrombosis, Department of Hematology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111809094046500_B1","first-page":"4","article-title":"Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.","volume":"84","author":"Middeldorp","year":"2000","journal-title":"Thromb Haemost"},{"issue":"1","key":"2019111809094046500_B2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0037-1613960","article-title":"A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.","volume":"84","author":"Tans","year":"2000","journal-title":"Thromb Haemost"},{"issue":"1","key":"2019111809094046500_B3","first-page":"9","article-title":"Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.","volume":"84","author":"Meijers","year":"2000","journal-title":"Thromb Haemost"},{"key":"2019111809094046500_B4","article-title":"WHO Expert Group Medical eligibility criteria for contraceptive use.","volume-title":"Reproductive Health and Research","year":"2009","edition":"4th ed"},{"issue":"8935","key":"2019111809094046500_B5","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(94)90286-0","article-title":"Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation.","volume":"344","author":"Vandenbroucke","year":"1994","journal-title":"Lancet"},{"issue":"3","key":"2019111809094046500_B6","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.ATV.19.3.700","article-title":"Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis.","volume":"19","author":"Martinelli","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2019111809094046500_B7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.160.1.49","article-title":"Higher risk of venous thrombosis during early use of oral contraceptives in women with hereditary clotting defects.","volume":"160","author":"Bloemenkamp","year":"2000","journal-title":"Arch Int Med"},{"issue":"2","key":"2019111809094046500_B8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13625180008500383","article-title":"Are factor V Leiden carriers who use oralcontraceptives at extreme risk of venous thromboembolism?","volume":"5","author":"Spannagl","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"9","key":"2019111809094046500_B9","first-page":"965","article-title":"Risk of thrombosis associated with oral contraceptives in women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G2210A mutation of the prothrombin gene.","volume":"86","author":"Santamaria","year":"2001","journal-title":"Haematologica"},{"issue":"12","key":"2019111809094046500_B10","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1053\/euhj.2001.3082","article-title":"Venous thromboembolism in young women: role of thrombophilic mutations and oral contraceptive use.","volume":"23","author":"Legnani","year":"2002","journal-title":"Eur Heart J"},{"issue":"1","key":"2019111809094046500_B11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.contraception.2004.02.010","article-title":"Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.","volume":"70","author":"Sidney","year":"2004","journal-title":"Contraception"},{"issue":"9","key":"2019111809094046500_B12","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/j.1538-7836.2004.00852.x","article-title":"Familial thrombophilia and lifetime risk of venous thrombosis.","volume":"2","author":"Vossen","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2019111809094046500_B13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-145-11-200612050-00005","article-title":"Multicausal pathogenesis of venous thromboembolism. Evidence from a study in families with hereditary deficiencies of protein C, protein S, or antithrombin.","volume":"145","author":"Brouwer","year":"2006","journal-title":"Ann Int Med"},{"issue":"3","key":"2019111809094046500_B14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/archinte.167.3.282","article-title":"Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects.","volume":"167","author":"van Vlijmen","year":"2007","journal-title":"Arch Int Med"},{"issue":"1","key":"2019111809094046500_B15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.2007.06624.x","article-title":"High risk of pregnancy-related venous thromboembolism in women with multiple thrombophilic defects.","volume":"138","author":"Folkeringa","year":"2007","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111809094046500_B16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1783\/147118902101196216","article-title":"Clinical performance of the Nova T380 intrauterine device in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report.","volume":"28","author":"Cox","year":"2002","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"2","key":"2019111809094046500_B17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/13625181003708683","article-title":"State-of-the-art of non-hormonal methods of contraception: I. Mechanical barrier contraception.","volume":"15","author":"B\u00e1t\u00e1r","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"10","key":"2019111809094046500_B18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","article-title":"Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study.","volume":"143","author":"Heit","year":"2005","journal-title":"Ann Intern Med"},{"key":"2019111809094046500_B19","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study.","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"2019111809094046500_B20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7326\/0003-4819-128-1-199801010-00003","article-title":"The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis.","volume":"128","author":"Middeldorp","year":"1998","journal-title":"Ann Intern Med"},{"issue":"1","key":"2019111809094046500_B21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1538-7836.2004.01033.x","article-title":"Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis.","volume":"3","author":"Bank","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2019111809094046500_B22","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1001\/archinte.164.17.1932","article-title":"Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study.","volume":"164","author":"Bank","year":"2004","journal-title":"Arch Int Med"},{"issue":"2","key":"2019111809094046500_B23","first-page":"457","article-title":"The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects.","volume":"98","author":"Lijfering","year":"2007","journal-title":"Thromb Haemost"},{"issue":"12","key":"2019111809094046500_B24","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/oxfordjournals.aje.a008713","article-title":"Validated questionnaire for the identification of previous personal or familial venous thromboembolism.","volume":"143","author":"Frezzato","year":"1996","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2019111809094046500_B25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.thromres.2007.12.010","article-title":"Hyperhomocysteinemia is not a risk factor for venous and arterial thrombosis, and is associated with elevated factor VIII levels.","volume":"123","author":"Lijfering","year":"2008","journal-title":"Thromb Res"},{"issue":"6475","key":"2019111809094046500_B26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/369064a0","article-title":"Mutation in blood coagulation factor V associated with resistance to activated protein C.","volume":"369","author":"Bertina","year":"1994","journal-title":"Nature"},{"issue":"2","key":"2019111809094046500_B27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/clinchem\/44.2.349","article-title":"Reliable genotyping of the G-20210-A mutation of coagulation factor II (prothrombin).","volume":"44","author":"Danneberg","year":"1998","journal-title":"Clin Chem"},{"issue":"8943","key":"2019111809094046500_B28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","article-title":"Role of the clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis.","volume":"345","author":"Koster","year":"1995","journal-title":"Lancet"},{"key":"2019111809094046500_B29","first-page":"247","volume-title":"Modern Epidemiology","author":"Rothman","year":"1998","edition":"2nd ed"},{"issue":"9159","key":"2019111809094046500_B30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(98)10266-0","article-title":"Venous thrombosis: a multicausal disease.","volume":"353","author":"Rosendaal","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"2019111809094046500_B31","first-page":"744","article-title":"(Groupe d'Etude de la Thrombose de Bretagne Occidentale). Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden.","volume":"96","author":"Couturaud","year":"2006","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111809094046500_B32","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1046\/j.1365-2141.2000.02502.x","article-title":"The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both.","volume":"111","author":"Martinelli","year":"2000","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111809094046500_B33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1055\/s-0037-1614442","article-title":"Incidence of venous thromboembolism in families with inherited thrombophilia.","volume":"81","author":"Simioni","year":"1999","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111809094046500_B34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2008.02921.x","article-title":"Pregnancy, the postpartum period and prothrombotic effects: risk of venous thrombosis in the MEGA study.","volume":"6","author":"Pomp","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111809094046500_B35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1538-7836.2007.02880.x","article-title":"The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A.","volume":"6","author":"Martinelli","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"19","key":"2019111809094046500_B36","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMra0707993","article-title":"Venous thromboembolic disease and pregnancy.","volume":"359","author":"Marik","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111809094046500_B37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/13625180903427675","article-title":"Efficacy of contraceptive methods: a review of the literature.","volume":"15","author":"Mansour","year":"2010","journal-title":"Eur J Contr Reprod Health Care"},{"issue":"2","key":"2019111809094046500_B38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1783\/147118902101196225","article-title":"Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report.","volume":"28","author":"Cox","year":"2002","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"2","key":"2019111809094046500_B39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2796.1995.tb00896.x","article-title":"Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties.","volume":"238","author":"Koster","year":"1995","journal-title":"J Int Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/8\/2055\/1348614\/zh803411002055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/8\/2055\/1348614\/zh803411002055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T01:02:09Z","timestamp":1592614929000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/8\/2055\/29462\/Thrombotic-risk-during-oral-contraceptive-use-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,25]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-03-345678","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,25]]}}}